Skip to content
10-K

Annual Report

Design Therapeutics, Inc. DSGN

0001193125-26-098491

← back to feed
Filed
Mar 9, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 2, 2026 61.67M sh
Shares Diluted FY 2025 · Dec 31, 2025 57.33M sh
Shares Diluted FY 2025 · Dec 31, 2024 56.59M sh
Capex FY 2025 · Dec 31, 2025 $193K
Capex FY 2025 · Dec 31, 2024 $340K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$54.36M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$43.11M
Cash And Equivalents FY 2025 · Dec 31, 2025 $16.86M
Cash And Equivalents FY 2025 · Dec 31, 2024 $22.56M
Stockholders Equity FY 2025 · Dec 31, 2025 $212.5M
Stockholders Equity FY 2025 · Dec 31, 2024 $242.1M
Stockholders Equity FY 2025 · Dec 31, 2023 $277.69M
Current Liabilities FY 2025 · Dec 31, 2025 $13.06M
Current Liabilities FY 2025 · Dec 31, 2024 $8.46M
Total Liabilities FY 2025 · Dec 31, 2025 $13.7M
Total Liabilities FY 2025 · Dec 31, 2024 $10M
Current Assets FY 2025 · Dec 31, 2025 $223.78M
Current Assets FY 2025 · Dec 31, 2024 $248.04M
Total Assets FY 2025 · Dec 31, 2025 $226.2M
Total Assets FY 2025 · Dec 31, 2024 $252.09M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.22
Eps Diluted FY 2025 · Dec 31, 2024 −$0.88
Eps Basic FY 2025 · Dec 31, 2025 −$1.22
Eps Basic FY 2025 · Dec 31, 2024 −$0.88
Sga Expense FY 2025 · Dec 31, 2025 $20.34M
Sga Expense FY 2025 · Dec 31, 2024 $18.03M
Rd Expense FY 2025 · Dec 31, 2025 $59.13M
Rd Expense FY 2025 · Dec 31, 2024 $44.35M
Net Income FY 2025 · Dec 31, 2025 −$69.79M
Net Income FY 2025 · Dec 31, 2024 −$49.59M
Operating Income FY 2025 · Dec 31, 2025 −$79.47M
Operating Income FY 2025 · Dec 31, 2024 −$62.38M